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SUMMARY
Background: Microalbuminuria (MA) is thought to be a marker of widespread vascular damage. It is associa-
ted with increased mortality in diabetes mellitus, hypertension and acute myocardial infarction. The aim of the
present study was to evaluate the prognostic significance of MA in non-diabetic acute stroke patients.
Material and methods: We studied 52 patients (mean age 69.3±12.5 years) diagnosed with ischemic stroke con-
firmed by computed tomography, who were admitted to the Stroke Unit within 24 hours after the onset of symp-
toms. The control group consisted of 37 age- and gender-matched subjects (mean age 65.2±5.7 years), exami-
ned 3 to 18 months after ischemic stroke. We excluded patients with diabetes mellitus, positive urinalysis, prote-
inuria, hepatic or renal insufficiency, neoplastic disease or clinical signs of infection. The severity of the neuro-
logical deficit was assessed by the Scandinavian Stroke Scale (SSS). The albumin excretion rate was measured
in daily urine collection on the second day of hospitalization, using the immunonephelometric method. The pa-
tients were followed up for three months.
Results: MA was found in 24 of 52 (46.1%) acute stroke patients and in 5 of 37 (13.5%) controls (p<0.05).
Patients with MA scored lower on the SSS than patients without MA, both on admission and later. We found
a correlation between the daily excretion of albumin and the severity of neurological deficit on admission, as
expressed by the SSS score (r = –0.48, p<0.05). The 90-day mortality rate was higher in patients with MA as
compared to patients without MA (45.8% vs 7.1%). Patients with MA scored lower on the Barthel Index on
Day 90 (median: 65 vs 100, p<0.01).
Conclusion: We found that MA can be detected in about 46% of non-diabetic patients with acute ischemic
stroke. Measuring the albumin excretion rate may be a reliable predictor of increased mortality 3 months
after stroke.
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BACKGROUND
Microalbuminuria (MA) is defined as a urinary
albumin excretion rate of 30 to 299 mg/day [1].
Several studies have shown that MA in diabetic
patients predicts diabetic nephropathy [2], as
well as increased cardiovascular and overall
mortality [2,3]. Persistent MA in diabetic patients
correlates with the presence of hypertension [4],
obesity, and dyslipidemia [5]. Hypertensive pa-
tients with MA more frequently develop left ven-
tricle hypertrophy and renal insufficiency [6].
The relationship between the presence of MA
and other atherosclerotic risk factors, such as hy-
pertension [7,8], dyslipidemia [9] and smoking
[10], is well documented in the general popula-
tion as well. Several studies have revealed the si-
gnificance of MA as a predictor of increased
mortality in hypertensive patients [11], and in el-
derly persons [12].
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MA is detected early in the course of acute my-
ocardial infarction [13,14] and is considered an in-
dependent predictor of early mortality in this con-
dition [14,15].
MA is thought to be a marker of widespread vascu-
lar damage [16]. It reflects the systemic transcapil-
lary leakage of albumin [16], and is frequently ac-
companied by an increased activity of the von Wil-
lebrand factor and/or factor VII, both known to be
markers of endothelial damage [17,18].
Little is known about the significance of MA in ce-
rebrovascular diseases. Epidemiological studies
suggest that MA can be regarded as a predictor of
ischemic stroke in diabetic and non-diabetic sub-
jects [19,20]. The thickness of the intima-media
complex in carotid arteries, which reflects the pro-
gression of atherosclerosis in these vessels, correla-
tes well with the presence of MA, as shown in
a study by Mykkanen et al. [21]. Beamer et al. ha-
ve recently proved that the prevalence of microal-
buminuria is three-fold greater in patients with re-
cent stroke when compared to controls with the
same profile of cardiovascular risk factors [22].
Since there are no data available regarding the po-
ssible prognostic significance of MA in acute ische-
mic stroke patients, the aim of the study was to
evaluate the prognostic significance of MA in non-
-diabetic acute stroke patients.
MATERIAL AND METHODS
Our research involved 52 patients (26 men and 26
women), aged from 41 to 89 years (mean age:
69.3±12.5), admitted to the Stroke Unit of the
Neurological Department within 24 hours after
stroke onset. In each case the diagnosis of stroke
was confirmed by computer tomography (CT). The
exclusion criteria were positive urinalysis including
hematuria, leucocyturia, positive nitrite reaction,
proteinuria, glycosuria, presence of diabetes melli-
tus, a history of inflammatory rheumatic disease,
the presence of liver or neoplastic disease, or any
sign of infection. The patient or caregiver was inte-
rviewed regarding past medical history to establish
the presence of any risk factors for stroke, such as
hypertension, ischemic heart disease, myocardial
infarction, or smoking. The control group consisted
of 37 age- and gender-matched subjects (12 men
and 25 women), aged from 57 to 75 years (mean:
65.2±5.7), examined 3 to 18 months after acute
stroke (median: 8 months). It has been widely re-
ported that all hematological and biochemical di-
sturbances which are recognized in the first few
days after stroke onset disappear a few weeks later,
so we decided to include in our control group pa-
tients more than 3 months after stroke.
All patients on admission (Day 0) had blood pres-
sure and electrocardiogram (ECG) taken, and we
noted the presence of atrial fibrillation. The severi-
ty of the neurological deficit was classified accor-
ding to the Scandinavian Stroke Scale (SSS) [23] on
Days 0, 1, 7, 14, and 30. The presence and severi-
ty of impaired consciousness were described ac-
cording to the appropriate item in the SSS [23].
After discharge from the hospital (5 to 91 days after
stroke onset, median=24 days) all survivors were
followed for three months. The outcome measures
on day 90 included mortality for any cause and the
capacity to perform the activities of daily living
(ADL) scored according to the Barthel Index [24].
Serum glucose levels were measured on admission
and on Days 1, 2, 3, 5, 7, and 14. Glycosylated he-
moglobin (HbA1) and fructosamine levels, hemato-
crit, white blood cell (WBC) count, urea, and lipids
profile were taken on Day 1 after 12 hours of fa-
sting.
Hematocrit and WBC were determined by an au-
tomated hematology analyzer (Cobas Vega Retic).
The Blood glucose level and urea were determined
by an automated chemistry analyzer (Hitachi 917).
HbA1 was measured by high-performance liquid
chromatography (Variant apparatus, Bio-Rad), and
the serum fructosamine level was measured by the
spectrophotometric method of Cobas Fara (Roche).
Total cholesterol, HDL-cholesterol and triglycerides
were assayed by the enzymatic method (CHOD-
-PAP) using commercially available kits (Boehrin-
ger-Mannheim; analyzer R A-1000). LDL-choleste-
rol was calculated by the Friedewald formula.
The albumin excretion rate was assessed in a 24-
-hour urine collection performed on Day 2. A 2-li-
ter plastic container was used to collect the urine,
and the volume was measured to the nearest 50
ml. The albumin concentrations were determined
by an immunonephelometric technique with com-
mercially available N antiserum to human albumin
(DADE Behring), with a sensitivity of 8 mg/L, intra-
-assay coefficient of 4.3% and inter-assay coeffi-
cient of 4.4%. The albumin excretion rate was
expressed as mg/24 hours. A daily urinary albumin
excretion below 30 mg was considered to be wi-
thin the normal range. MA was defined as an albu-
min urinary excretion rate between 30 and 299
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mg/24 hrs. [25]. Proteinuria was defined as a urina-
ry albumin excretion rate ≥300mg/24 hrs. [25]
All controls were screened for stroke risk factors
and were assessed for daily urinary albumin excre-
tion rate, fasting serum glucose, WBC count, total
cholesterol, LDL cholesterol, HDL cholesterol, and
triglycerides.
Statistical analysis 
Normally distributed data are expressed as the
mean±SD. The SSS scores and other data not nor-
mally distributed (Barthel Index score, albumin
excretion rate) were reported as the median value
with 25-75th percentiles. The Student’s t-test, Chi-
-square test, Mann-Whitney U test, Wilcoxon mat-
ched pairs test and Spearman correlation were per-
formed where appropriate. Statistical analysis was
performed using the STATISTICA computerized
statistical package for Windows.
RESULTS
MA was found in 24 of 52 stroke patients (46.1%)
and in 5 of 37 controls (13.5%) (p<0.05). Normal
urinary albumin excretion was found in 28 stroke
patients (53.9 %) and in 32 controls (86.5%),
(p<0.05). The detailed values of daily urinary albu-
min excretion are shown in table 1.
When we separately analyzed patients with MA
(group A), patients without MA (group B), and con-
trols (group C), we found that the patients with MA
were older than the patients without MA and the
controls. A correlation between age and daily
excretion of albumin in all stroke patients was fo-
und (r=0.45, p<0.01). No such correlation was fo-
und in the controls.
The 90-day mortality was higher in patients with
MA as compared to patients without MA (45.8%
vs. 7.1%).
More patients with MA showed evidence of atrial
fibrillation on ECG than did those without MA or
the controls. The study did not reveal any differen-
ce between patients with or without MA, or con-
trols, according to gender, incidence of hyperten-
sion, ischemic heart disease, or myocardial infarc-
tion (table 2).
Patients with MA scored lower on the SSS than pa-
tients without MA, both on admission and later.
During hospitalization, the neurological deficit in
survivors from each group improved slightly (table
3). We found a correlation between the daily
excretion of albumin and the SSS score on Day 0
in patients with MA (r=–0.48, p<0.05). Such
a correlation was not found in patients without
MA. There was a correlation between the SSS sco-
re and the age of the patients (r=–0.38, p<0.05),
and there was a difference on Day 0 in terms of di-
UAE (mg / 24 h)
(median; 25th – 75th percentile)
Patients without MA [A]; n = 28
Patients with MA [B]; n = 24
Whole study group [A+B]; n = 52
7.8 (6–14)
86.8 (53.5–143)
25.5 (7.65–85.7)
MA - microalbuminuria
Table 1. Urinary albumin excretion (UAE) in acute stroke patients.
With microalbuminuria
A n=24
Without microalbuminuria
B n=28
Day 0*
Day 1*
Day 7#
Day 14#
Day 30#
26;   9-38
21; 10-40
26; 10-42
37; 25-46
40; 28-50
39; 27-44
39; 27-45
46; 40-51
50; 45-56
55; 46-58
*A-B, p£0.05; #A-B, p£0.001
Table 3. Scandinavian Stroke Scale scores (median value; 25th –75th
percentile) in patients with microalbuminuria [A] and without
microalbuminuria [B] (Mann –Whitney U test).
With
microalbuminuria
A
n=24
Without
microalbuminuria
B
n=28
Controls
C
n=37
Age (years)*
Gender (males)
History of hypertension
History of ischemic heart
disease
History of myocardial
infarction
ECG evidence of atrial
fibrillation
Death at 90 days
HbA1 (%) on Day 1
Fructosamine (mmol/l)
on Day 1
73.3±11.6
12 (50%)
17 (70.8%)
9 (37.5%)
0
10 (41.7%)#
11 (45.8%)**
6.0±0.9
275±34.3
66.0±12.4
14 (50%)
16 (57.0%)
15 (53.6%)
1 (3.6%)
2 (7.1%)
2 (7.1%)
6.0 ± 1.2
272 ± 37
#A-B - χ2=8.68,p=0.0032;   A-C -  χ2=13.02, p=0.0002
* A-B, A-C, B-C, p<0.05 (Student’s t-test)
**A-B -  χ2=10.32, p=0.0013
Table 2. Baseline characteristics and outcome in patients with
microalbuminuria [A], without microalbuminuria [B], 
and in controls [C].
65.2±5.5
25 (67.5%)
27 (73.0%)
16 (43.3%)
3 (8.1%)
0
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minished consciousness between patients with and
without MA (35.5% vs. 14.3% respectively, p<0.05).
We did not find any differences in the distribution
of systemic complications recorded during hospita-
lization. Patients with MA scored lower on the Bar-
thel Index on Day 90 than those without MA (me-
dian=65 vs. 100, p£0.01).
The 90-day mortality rate was higher in patients
with MA as compared to patients without MA
(45.8% vs. 7.1%; p<0.05).
DISCUSSION
MA has traditionally been a marker for monitoring
diabetes mellitus [26,27] Our study is the first to
evaluate the prognostic significance of MA in non-
-diabetic acute stroke patients. In our study we no-
ted with interest the very high prevalence of MA
(about 46%) in non-diabetic acute stroke patients,
as opposed to only 13.5% of the controls, who we-
re several months after their stroke. Interestingly,
a similar very high prevalence of microalbuminuria
in stroke patients was noted by Beamer at al, who
found microalbuminuria in about 30% of stroke
patients and in 10% of controls matched for stroke
risk factors [22].
An increased albumin urinary excretion rate is two-
to four-fold less likely to occur in the general popu-
lation than in non-diabetic acute stroke patients
[25] The prevalence of MA varies widely between
ethnic groups, and ranges from 2.2% to 10.2% in
Britain [11,28], up to 39% and 42% in Aboriginal
women and men respectively [29]. It has been do-
cumented in several studies that MA in the general
population correlates with factors that increase the
risk for atherosclerotic diseases, such as high blood
pressure [30], obesity [25], high triglyceride levels
[7], low HDL cholesterol levels [25], raised serum
insulin levels [7,30] and carotid artery (intima+me-
dia) thickness [21].
MA in the diabetic population is a predictor of the
development of persistent clinical proteinuria, con-
sequent renal disease, and increased risk of cardio-
vascular death [1]. Mykkanen et al, in a study of
1449 patients aged from 40 to 69 years, showed
a higher prevalence of MA in diabetic than in non-
-diabetic patients (27.6 vs. 13.9%) [21]. In the pre-
sent study we excluded patients with diabetes mel-
litus in order to obtain a group of patients without
the additional risk of cardiovascular death related
to MA in the course of diabetes mellitus.
In the non-diabetic population, MA is seen in pa-
tients with atherosclerotic vascular diseases, such
as hypertension [31], coronary artery disease [11],
peripheral arterial diseases [11], and obesity [31].
The mechanism underlying MA in this population
remains unknown, but Kofoed-Enevoldsen et al.
proposed that MA in the non-diabetic population
is associated with the loss of glomerular charge se-
lectivity due to the loss of heparan sulfate [32]. The
latter is thought to be a non-specific marker of wi-
despread vascular damage or of endothelial dys-
function [18].
Very few clinical reports have documented that
MA is a risk factor for ischemic stroke. Miettinen et
al, in a study of 1375 non diabetic and 1056 dia-
betic patients with a seven-year follow-up, showed
that proteinuria (>150mg/L) in diabetic patients
doubles the risk for vascular accidents. The risk of
stroke, both in patients with diabetes mellitus and
in non-diabetics, was higher with proteinuria
>300mg/L [19]. Many clinical studies have identi-
fied MA as a risk factor for death, independent of
classic cardiovascular risk factors, not only in pa-
tients with non insulin-dependent diabetes mellitus
[2,3,33], but also in non-diabetics [11]. The pro-
gnostic significance of MA in a non-diabetic acute
stroke population has not previously been studied.
Our data indicate a very high prevalence of MA in
acute stroke when compared to age- and gender-
-matched controls, the latter being assessed several
months after stroke. Data concerning the prevalen-
ce of MA in the non-diabetic Polish population are
not available.
In our group of patients with acute stroke, the high
prevalence of MA could be related to the very
common presence of hypertension or ischemic he-
art disease; however, when we compared patients
with and without MA we did not find any differen-
ces in the distribution of these stroke risk factors
among the two group. We also did not find a high
prevalence of MA in the controls, despite the fact
that they had a similar distribution of stroke risk
factors, that is hypertension and ischemic heart di-
sease.
Based on the evidence from studies on patients
with acute myocardial infarction, MA in the acute
phase of stroke may be a marker of the inflammato-
ry response. Berton at al, in a study of 360 patients
with acute myocardial infarction and 136 controls,
found a significantly higher albumin excretion rate
on both the first and third day after myocardial in-
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farction, than in the control group. No difference in
the albumin excretion rate between patients with
myocardial infarction and controls was present on
the seventh day [14]. In our study, MA in acute
stroke patients was assessed on Day 2, and we may
speculate that the increase is due at least partly to
an acute phase inflammatory response. According
to Gosling et al, MA in acute myocardial infarction
is a consequence of the inflammatory reaction that
accompanies acute myocardial infarction, and invo-
lves the renal vascular system [13]. The adverse re-
lation between mortality and MA found in patients
with acute myocardial infarction supports the pro-
bability of a similar relation in the acute phase of
stroke. An albumin excretion rate >50mg/24 hours
significantly increases the risk of death in patients
with acute myocardial infarction. Berton et al. sho-
wed that among 26 patients with acute myocardial
infarction who died during hospitalization, MA was
present in 24 [14].
The significant correlation we discovered between
MA on Day 2 and the neurological deficit in the
SSS score on Day 0 (r=–0.41, p≤0.001) and on
Day 1 (r=–0.35, p≤0.001) supports the argument
that MA reflects the severity of stroke and is a mar-
ker of the acute inflammatory response.
Another feature of our study was the correlation be-
tween the greatly older age of patients with MA
compared to patients with a normal albumin excre-
tion rate. There are only a few studies examining the
influence of age on the albumin excretion rate in the
general population, but most authors seem to be in
agreement that urinary albumin concentrations may
decline with age [31]; however, a recently published
study shows that age is an independent factor for
the presence of microalbuminuria in stroke patients
[22]. In our study this strong correlation between
age and MA may not necessarily represent a cause-
-effect relationship, but may be due to the pheno-
menon of older patients having a worse neurological
deficit, which also strongly correlates with age.
The relation between increased albumin excretion
rate, lower outcome test scores, and a higher 90-day
mortality rate may be related to the more advanced
age of patients with increased albumin excretion, or
to the worse neurological deficit during the course
of the disease, or both. Whether MA is an indepen-
dent prognostic indicator of poor outcome in stroke
patients remains to be established.
CONCLUSIONS
We have shown that MA was found in about 46%
of non-diabetic acute ischemic stroke patients. Me-
asuring the albumin excretion rate in the acute
phase of stroke may be a reliable predictor of hi-
gher mortality 3 months after stroke.
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